Monoclonal anti-T cell antibodies have been used successfully in vivo to suppress many immune responses. In humans, OKT3 has been shown to be a potent agent for the reversal of acute rejection. In mice, monoclonal antibodies have been used to suppress T-dependent B cell responses and to prolong skin graft survival. Based on this experience, experiments were performed to examine whether allogeneic bone marrow chimeras might be created using monoclonal anti-T cell antibodies in vivo to replace whole body irradiation.
|Original language||English (US)|
|Number of pages||4|
|State||Published - 1988|
ASJC Scopus subject areas